Mometasone furoate nasal spray for nasal polyposis

References

• Bachert C, Hörmann K, Mösges R et al. An update on the diagnosis and treatment of sinusitis and nasal polyposis. Allergy58, 176–191 (2003).
   PubMed Web of Science ®Google Scholar
• Fokkens W, Lund V, Mullol J et al. European position paper on rhinosinusitis and nasal polyps 2007. Rhinology20(Suppl.) 1–136 (2007).
   PubMed Web of Science ®Google Scholar
• Pawankar R. Nasal polyposis: an update: editorial review. Curr. Opin. Allergy Clin. Immunol.3, 1–6 (2003).
   PubMedGoogle Scholar
• Bachert C, Gevaert P, Zhang N, van Zele T, Perez-Novo C. Role of staphylococcal superantigens in airway disease. Chem. Immunol. Allergy93, 214–236 (2007).
   Google Scholar
• Norlander T, Westrin KM, Fukami M, Stierna P, Carlsoo B. Experimentally induced polyps in the sinus mucosa: a structural analysis of the initial stages. Laryngoscope106(2 Pt 1), 196–203 (1996).
   PubMedGoogle Scholar
• Krouse J, Naclerio R, Friedman HS. Patterns of care and associated costs for treating patients with nasal polyps. European Academy of Allergology and Clinical Immunology. Vienna, Austria. Poster presentation (2006).
   Google Scholar
• Berggren F, Johansson L. Cost effectiveness of nasal budesonide versus surgical treatment for nasal polyps. Pharmacoeconomics21, 351–356 (2003).
   Google Scholar
• Alobid I, Benítez P, Valero A et al. The impact of atopy, sinus opacification, and nasal patency on quality of life in patients with severe nasal polyposis. Otolaryngol. Head Neck Surg.134, 609–612 (2006).
   Google Scholar
• Hedman J, Kaprio J, Poussa T. Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int. J. Epidemiol.28, 717–722 (1999).
   PubMed Web of Science ®Google Scholar
• Johansson L, Åkerlund A, Holmberg K, Melén I, Bende M. Prevalence of nasal polyps in adults: The Skövde population-based study. Ann. Otol. Rhinol. Laryngol.112, 625–629 (2003).
   PubMed Web of Science ®Google Scholar
• Klossek JM, Neukirch F, Pribil C et al. Prevalence of nasal polyposis in France: a cross-sectional case–control study. Allergy60, 233–237 (2005).
   PubMed Web of Science ®Google Scholar
• Dalziel K, Stein K, Round A et al. Systemic review of endoscopic sinus surgery for nasal polyps. Health Technol. Assess.7, 1–159 (2003).
   Google Scholar
• Mygind N, Lund V. Intranasal corticosteroids for nasal polyposis: biological rationale, efficacy, and safety. Treat. Respir. Med.5, 93–102 (2006).
   Google Scholar
• De Leng WW, Westerman AM, Weterman M et al. Nasal polyposis in Peutz-Jeghers syndrome: a distinct histopathologic and molecular genetic entity. J. Clin. Pathol.60(4), 392–396 (2007).
   Google Scholar
• Samter M, Beers RF. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann. Intern. Med.68, 875–883 (1968).
   Google Scholar
• Holmström M, Holmberg K, Lundblad L, Norlander T, Stierna P. Current perspectives on the treatment of nasal polyposis: a Swedish opinion report. Acta Otolaryngol.122, 736–744 (2002).
   PubMed Web of Science ®Google Scholar
• Patiar S, Reece P. Oral steroids for nasal polyps. Cochrane Database Syst. Rev.24, CD005232 (2007).
   Google Scholar
• Hissaria P, Smith W, Wormald PJ et al. Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures. J. Allergy Clin. Immunol.118, 128–133 (2006).
   PubMed Web of Science ®Google Scholar
• Alobid I, Benítez P, Pujols L et al. Severe nasal polyposis and its impact on quality of life. The effect of a short course of oral steroids followed by long-term intranasal steroid treatment. Rhinology44, 8–13 (2006).
   PubMed Web of Science ®Google Scholar
• Albertien AC, Aukema MD, Mulder PGH, Fokkens WJ. Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone proprionate nasal drops reduces need for sinus surgery. J. Allergy Clin. Immunol.115, 1017–1023 (2005).
   Google Scholar
• Bellodi S, Tosca MA, Pulvirenti G et al. Activity of budesonide on nasal neutrophilic inflammation and obstruction in children with recurrent upper airway infections. A preliminary investigation. Int. J. Pediatr. Otorhinolaryngol.70, 445–452 (2006).
   Google Scholar
• Pien LC. How long can my patient use intranasal steroid sprays? Cleve. Clin. J. Med.72, 1079–1082 (2005).
   Google Scholar
• Boner AL. Effects of intranasal corticosteroids on the hypothalamic–pituatary adrenal axis in children. J. Allergy Clin. Immunol.108, 32–39 (2001).
   PubMed Web of Science ®Google Scholar
• Skoner D, Rachelefsky G, Meltzer EO et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics105, E23 (2000).
   PubMed Web of Science ®Google Scholar
• Elocon® (mometasone furoate). 0.1% paste, salve or cutaneous solution. Product Information, Schering Corporation, NJ 07033, USA (2002).
   Google Scholar
• Meltzer EO, Wenzel S. The efficacy and safety of mometasone furoate delivered via a dry powder inhaler for the treatment of asthma. J. Asthma43, 765–772 (2006).
   PubMed Web of Science ®Google Scholar
• NASONEX® (mometasone furoate monohydrate) Nasal Spray, 50 µg. Product Information. Schering Corporation, NJ 07033, USA (2005).
   Google Scholar
• Schenkel E. Features of mometasone furoate nasal spray and its utility in the management of allergic rhinitis. Expert Opin. Pharmacother.4, 1579–1591 (2003).
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J. Allergy Clin. Immunol.116, 1289–1295 (2005).
   PubMed Web of Science ®Google Scholar
• McCormack PL, Plosker GL. Inhaled mometasone furoate: a review of its use in persistent asthma in adults and adolescents. Drugs.66, 1151–1168 (2006).
   PubMed Web of Science ®Google Scholar
• Szefler SJ. Pharmacokinetics of intranasal corticosteroids. J. Allergy Clin. Immunol.108(Suppl. 1), S26–S31 (2001).
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Kunka RL, Yin Y, Andrews SM, Callejas S, Ng C. Bioavailability of fluticasone priopionate and mometasone furoate aqueous nasal sprays. Eur. J. Clin. Pharmacol.60, 265–268 (2004).
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf.23, 11–33 (2000).
   PubMed Web of Science ®Google Scholar
• Teng XW, Cutler DJ, Davies NM. Mometasone furoate degradation and metabolism in human biological fluids and tissues. Biopharm. Drug Dispos.24, 321–333 (2003).
   PubMed Web of Science ®Google Scholar
• Teng XW, Cutler DJ, Davies NM. Kinetics of metabolism and degradation of mometasone furoate in rat biological fluids and tissues. J. Pharm. Pharmacol.55, 617–630 (2003).
   Google Scholar
• Sahasranaman S, Issar M, Hochhaus G. Metabolism of mometasone furoate and biological activity of the metabolites. Drug Metab. Dispos.34, 225–233 (2006).
   PubMed Web of Science ®Google Scholar
• Issar M, Sahasranaman S, Buchwald P, Hochhaus G. Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur. Respir. J.27, 511–516 (2006).
   PubMedGoogle Scholar
• Austin RJ, Mashera B, Walker A et al. Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur. Respir. J.20, 1386–1392 (2002).
   PubMed Web of Science ®Google Scholar
• Bonfils P, Halimi P, Malinvaud D. Adrenal suppression and osteoporosis after treatment of nasal polyposis. Acta Otolaryngol.126, 1195–1200 (2006).
   PubMed Web of Science ®Google Scholar
• Schenkel EJ, Skoner DP, Bronsky EA et al. Absence of growth retardation in children with perennial allergic rhiniitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics105, E22 (2000).
   PubMed Web of Science ®Google Scholar
• Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin. Ther.19, 1330–1339 (1997).
   PubMed Web of Science ®Google Scholar
• Small CB, Hernandez J, Reyes A et al. Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J. Allergy Clin. Immunol.116, 1275–1281 (2005).
   PubMed Web of Science ®Google Scholar
• Stjärne P, Mosges R, Jorissen M et al. A randomized controlled trial of mometasone furoate nasal spray for the treatment of nasal polyposis. Arch. Otolaryngol. Head Neck Surg.132, 179–185 (2006).
   PubMedGoogle Scholar
• Stjärne P, Blomgren K, Cayé-Thomasen P, Salo S, Søderstrøm T. The efficacy and safety of once-daily mometasone furoate nasal spray in nasal polyposis: a randomized, double-blind, placebo-controlled study. Acta Otolaryngol.126, 606–612 (2006).
   PubMed Web of Science ®Google Scholar
• Jankowski R, Schrewelius C, Bonfils P et al. Efficacy and tolerability of budesonide aqueous nasal spray treatment in patients with nasal polyps. Arch. Otolaryngol. Head Neck Surg.127, 447–452 (2001).
   PubMedGoogle Scholar
• Derendorf H, Daley-Yates PT, Pierre LN, Efthimou J. Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology. J. Clin. Pharmacol.42, 383–387 (2002).
   PubMed Web of Science ®Google Scholar
• Nielsen LP, Mygind N, Dahl R. Intranasal corticosteroids for allergic rhinitis: superior relief? Drugs61, 1563–1579 (2001).
   PubMedGoogle Scholar
• Minshall E, Ghaffar O, Cameron L et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg.118, 648–654 (1998).
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Richards DH. Relationship between systemic corticosteroid exposure and growth velocity: development of a pharmacokinetic/pharmacodynamic model. Clin. Ther.26, 1905–1919 (2004).
   PubMed Web of Science ®Google Scholar
• Ponikau JU, Sherris DA, Kita H, Kern EB. Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis. J. Allergy Clin. Immunol.110, 862–866 (2002).
   PubMed Web of Science ®Google Scholar
• Nucera E, Schiavino D, Milani et al. Effects of lysine-acetylsalicylate (LAS) treatment in nasal polyposis: two controlled long term prospective follow up studies. Thorax55(Suppl. 2), S75–S78 (2000).
   PubMedGoogle Scholar
• Baudoin T, Kalogjera L, Hat J. Capsaicin significantly reduces sinonasal polyps. Acta Otolaryngol.120, 307–311 (2000).
   PubMed Web of Science ®Google Scholar
• Gevaert P, Lang-Loidolt D, Lackner A et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J. Allergy Clin. Immunol.118, 1133–1141 (2006).
   PubMed Web of Science ®Google Scholar
• Passali D, Bernstein JM, Passali FM, Damiani V, Passali GC, Bellussi L. Treatment of recurrent chronic hyperplastic sinusitis with nasal polyposis. Arch. Otolaryngol. Head Neck Surg.129, 656–659 (2003).
   PubMed Web of Science ®Google Scholar
• Fokkens W, Lund V, Bachert C et al. EAACI position paper on rhinosinusitis and nasal polyps. Executive summary. Allergy60, 583–601 (2005).
   Google Scholar